Get the Stockscreener App
1.21
3.97%
-0.05
After Hours:
1.27
0.06
+4.96%
Unity Biotechnology Inc stock is traded at $1.21, with a volume of 113.09K.
It is down -3.97% in the last 24 hours and down -17.12% over the past month.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.
See More
Previous Close:
$1.26
Open:
$1.15
24h Volume:
113.09K
Relative Volume:
2.65
Market Cap:
$20.39M
Revenue:
-
Net Income/Loss:
$-52.53M
P/E Ratio:
-0.3048
EPS:
-3.97
Net Cash Flow:
$-39.93M
1W Performance:
-13.57%
1M Performance:
-17.12%
6M Performance:
-24.84%
1Y Performance:
-41.26%
1-Day Range:
$1.12
$1.25
1-Week Range:
$1.12
$1.40
52-Week Range:
$1.12
$2.26
Unity Biotechnology Inc Stock (UBX) Company Profile
Name
Unity Biotechnology Inc
Sector
Industry
Phone
(650) 416-1192
Address
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-22 | Upgrade | ROTH Capital | Neutral → Buy |
| Nov-10-21 | Upgrade | Mizuho | Neutral → Buy |
| Jun-28-21 | Upgrade | Citigroup | Sell → Buy |
| Jun-07-21 | Initiated | H.C. Wainwright | Buy |
| Feb-16-21 | Downgrade | Citigroup | Neutral → Sell |
| Aug-18-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-18-20 | Downgrade | Mizuho | Buy → Neutral |
| Aug-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-17-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-28-20 | Initiated | ROTH Capital | Buy |
| Dec-12-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-07-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Initiated | Mizuho | Buy |
| May-29-18 | Initiated | Citigroup | Buy |
| May-29-18 | Initiated | Goldman | Neutral |
| May-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Unity Biotechnology Inc Stock (UBX) Latest News
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth? - Simply Wall St
Unity Biotechnology Focuses on Promising DME Treatment - TipRanks
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 - The Manila Times
UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Age-related Macular Degeneration Market Size is Set for Rapid - openPR
Empery Asset Management LP Acquires Shares in Tonix Pharmaceuticals - Yahoo Finance UK
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial - Ophthalmology Times
Empery Asset Management, LP Acquires Shares in Volcon Inc - Yahoo Finance UK
Empery Asset Management's Strategic Acquisition in Elevation Oncology - Yahoo Finance
Empery Asset Management's Strategic Reduction in Sharps Technology Inc - Yahoo Finance
UNITY Biotechnology to Host In-Person Ophthalmology Day in New York on Tuesday, October 15, 2024 - GlobeNewswire
Unity Biotechnology (FRA:9U90) Cash Ratio : 3.85 (As of Jun. 2024) - GuruFocus.com
Jefferies Financial Group Boosts United Therapeutics (NASDAQ:UTHR) Price Target to $432.00 - Defense World
Tri Locum Partners LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Epoch Investment Partners Inc. Increases Stake in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Mercer Global Advisors Inc. ADV - Defense World
Symmetry Investments LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
American Century Companies Inc. Has $13.14 Million Position in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Pacer Advisors Inc. Grows Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Meiji Yasuda Asset Management Co Ltd. Buys 33 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Longevity and Anti-Senescence Therapy Market Share, Size, Growth, and Forecast to 2031 - InsightAce Analytic
Inspire Investing LLC Acquires 2,936 Shares of United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Uniti Group Inc [UNIT] stock was sold by Mudry Ronald J. at the price of US$0.11 million - Knox Daily
1,054 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Choreo LLC - Defense World
Quest Partners LLC Has $89,000 Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Liquidia Corp faces renewed legal challenge from United Therapeutics By Investing.com - Investing.com Australia
Meeder Advisory Services Inc. Invests $36,000 in Uniti Group Inc. (NASDAQ:UNIT) - Defense World
Unity Software Inc. (NYSE:U) Shares Bought by Daiwa Securities Group Inc. - Defense World
Commonwealth Equity Services LLC Has $1.16 Million Position in Unity Software Inc. (NYSE:U) - Defense World
Court rules against United Therapeutics in Liquidia case - Investing.com India
Royal London Asset Management Ltd. Boosts Stake in Unity Software Inc. (NYSE:U) - Defense World
694 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Caprock Group LLC - Defense World
Anti-Senescence Therapy Market is Likely to Upsurge at USD 25.16 Bn- Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa – Daily News Mirror - Daily News Mirror
The Top 8 Things to Know About Anti-Aging Research Right Now - upworthyscience.com
UBX (Unity Biotechnology) Debt-to-Equity : 1.10 (As of Jun. 2024) - GuruFocus.com
Billionaires are spending big so they — and maybe you — can live forever - MarketWatch
Unity Biotechnology (FRA:9U90) Net-Net Working Capital : €0.01 (As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
UBX (Unity Biotechnology) EPS (Basic) : $-1.74 (TTM As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) COGS-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) Growth Rank : 0 (As of Aug. 17, 2024) - GuruFocus.com
UBX (Unity Biotechnology) Short-Term Debt & Capital Lease O - GuruFocus.com
UBX (Unity Biotechnology) Purchase Of Investment : $-28.03 Mil (TTM As of Jun. 2024) - GuruFocus.com
UBX (Unity Biotechnology) Intrinsic Value: Projected FCF : $-30.17 (As of Aug. 17, 2024) - GuruFocus.com
Unity Biotechnology (FRA:9U90) Cash From Discontinued Inves - GuruFocus.com
UBX (Unity Biotechnology) GF Value : $0.00 (As of Aug. 16, 2024) - GuruFocus.com
UNITY Biotechnology to Participate in Upcoming Investor Conferences - GlobeNewswire
UNITY Biotechnology (UBX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Unity Biotechnology, Inc. Expected to Post Q3 2024 Earnings of ($0.40) Per Share (NASDAQ:UBX) - Defense World
Unity Biotechnology (NASDAQ:UBX) Posts Earnings Results - Defense World
FY2028 EPS Estimates for Unity Biotechnology, Inc. (NASDAQ:UBX) Boosted by Analyst - Defense World
Unity Biotechnology Inc Stock (UBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):